<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Qinlock</title>
    <link rel="shortcut icon" href="images/testlogo.png" type="image/x-icon">
    <link rel="stylesheet" href="css.css">
    <style>
        body {
            background-color: rgba(196, 241, 255, 0.562);
        }
        .container {
            text-align: center;
            margin-left: 100px;
            margin-right:100px;
        }
        p {
            font-size: 22px; /* Adjust the font size as desired */
            font-style: italic;
            text-align: justify;
            text-justify: inter-word;
        }
        table {
        border-spacing: 30px;
        }
    </style>
</head>
<body>
    <center>
        <h1>Qinlock</h1><br>
        <table>
            <tr>
                <td><img src="https://www.empr.com/wp-content/uploads/sites/7/2020/06/ff106379571a43148af6c05e5dc532d7-Qinlock_box-bot.jpg" alt=""></td>
                <!-- <td><img src="n1.2.jpeg" alt=""></td> -->
            </tr>
        </table>
            <div class="container">
                <p>
                    Qinlock is specifically approved for the treatment of adult patients who have received prior treatment for GISTs but have experienced tumor growth or are unable to tolerate other available therapies. It is indicated for use when other treatments, such as imatinib, sunitinib, and regorafenib, have not been effective or are not suitable for the patient.
                </p>
            </div>
    </center>
    
</body>
</html>